HomeCompareCYCCP vs ADC

CYCCP vs ADC: Dividend Comparison 2026

CYCCP yields 5.94% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $158.2K in total portfolio value· pulled ahead in Year 2
10 years
CYCCP
CYCCP
● Live price
5.94%
Share price
$5.05
Annual div
$0.30
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.7K
Annual income
$0.61
Full CYCCP calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — CYCCP vs ADC

📍 ADC pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYCCPADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYCCP + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYCCP pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYCCP
Annual income on $10K today (after 15% tax)
$504.95/yr
After 10yr DRIP, annual income (after tax)
$0.52/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,677.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYCCP + ADC for your $10,000?

CYCCP: 50%ADC: 50%
100% ADC50/50100% CYCCP
Portfolio after 10yr
$99.8K
Annual income
$40,398.96/yr
Blended yield
40.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

CYCCP
No analyst data
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYCCP buys
0
ADC buys
0
No recent congressional trades found for CYCCP or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYCCPADC
Forward yield5.94%4.13%
Annual dividend / share$0.30$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.4%
Portfolio after 10y$20.7K$178.9K
Annual income after 10y$0.61$80,797.29
Total dividends collected$604.00$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: CYCCP vs ADC ($10,000, DRIP)

YearCYCCP PortfolioCYCCP Income/yrADC PortfolioADC Income/yrGap
1$10,997$297.03$10,990$580.36+$7.00CYCCP
2← crossover$11,919$152.64$12,301$860.26$382.00ADC
3$12,831$77.31$14,104$1,298.62$1.3KADC
4$13,768$38.89$16,691$2,008.16$2.9KADC
5$14,751$19.50$20,580$3,205.09$5.8KADC
6$15,794$9.76$26,754$5,330.02$11.0KADC
7$16,904$4.88$37,196$9,345.14$20.3KADC
8$18,090$2.44$56,244$17,523.09$38.2KADC
9$19,358$1.22$94,286$35,736.21$74.9KADC
10$20,713$0.61$178,949$80,797.29$158.2KADC

CYCCP vs ADC: Complete Analysis 2026

CYCCPStock

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Full CYCCP Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this CYCCP vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYCCP vs SCHDCYCCP vs JEPICYCCP vs OCYCCP vs KOCYCCP vs MAINCYCCP vs NNNCYCCP vs EPRTCYCCP vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.